Loading...
In several trials, combining an angiotensin-converting–enzyme (ACE) inhibitor and an angiotensin-receptor blocker (ARB) failed to improve clinically important renal outcomes. In this latest study, U.S. researchers examined combined therapy in nearly 1500 patients with type 2 diabetes, estimated glomerular filtration (GFR) rates between 30 and 90 mL/min/1.73 m2, and proteinuria (≥300 mg albumin per g creatinine). Patients were randomized to receive losartan plus lisinopril or losartan plus placebo. Doses were titrated to a maximum of 100 mg for losartan and 40 mg for lisinopril.
The study was stopped because of safety concerns after median follow-up of 2.2 years. At that point, no significant difference was found between groups in a combined …